Clinical Trial Update: Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating nivolumab with or without ipilimumab in metastatic or unresectable sarcoma shows results from a completed study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Sarcoma
• Bone Sarcoma Ajcc V7
• Dedifferentiated Liposarcoma
• Gastrointestinal Stromal Tumor
• Liposarcoma
• Pleomorphic Liposarcoma
• Soft Tissue Sarcoma
• Soft Tissue Sarcoma Ajcc V7
• Soft-tissue Sarcoma
• Stage Iva Bone Sarcoma Ajcc V7
• Stage Ivb Bone Sarcoma Ajcc V7
• Undifferentiated Pleomorphic Sarcoma
• Unresectable Bone Sarcoma
• Unresectable Dedifferentiated Liposarcoma
• Unresectable Liposarcoma
• Unresectable Malignant Gastrointestinal Stromal Tumor
• Unresectable Sarcoma
• Unresectable Soft Tissue Sarcoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma | Phase 2 | Status: COMPLETED | Results posted: 2020-06-16